Clinically, PARP inhibitors (PARPi), such as olaparib, niraparib, rucaparib, and talazoparib, exploit synthetic lethality in homologous recombination–deficient tumors and are increasingly applied in ovarian, breast, prostate, and pancreatic cancers. The gene discussed is PARP1; the disease is familial pancreatic carcinoma.